Robert joined BayPAT as Managing Director in January 2017, coming from Lophius Biosciences, aVC-backed clinical-stage biotech company developing T-cell-based in vitro diagnostics, where he served asCEO. Prior to that, he was Head of Business Development and Licensing at SuppreMol, responsible for the partnering process, where he led the initial discussions and negotiations that ultimately resulted in the EUR 200m acquisition of the company by Baxalta.
Robert is a biochemist by training and is a Certified Licensing Professional (CLP). He has 20 years’ experience in the life sciences industry, over 15 years of which is in business development and licensing.
Robert received his PhD in Biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institut in Germany and held a research position as a post-doctoral fellow at the Medical University of South Carolina, USA.